422 related articles for article (PubMed ID: 38550587)
21. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma.
Wang T; Xia K; Qiu T; Han S; Chen Z; Ma X; Zhang L; Zou J; Zhang Y; Yu B; Kong C; Guo J; Liu Y; Zhou J; Zheng S
Aging (Albany NY); 2023 Sep; 15(17):8930-8947. PubMed ID: 37688769
[TBL] [Abstract][Full Text] [Related]
25. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
[TBL] [Abstract][Full Text] [Related]
26. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
Front Immunol; 2022; 13():943066. PubMed ID: 36159865
[TBL] [Abstract][Full Text] [Related]
27. Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies.
Gorji L; Brown ZJ; Pawlik TM
Surg Oncol; 2024 Feb; 52():102031. PubMed ID: 38128340
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
[TBL] [Abstract][Full Text] [Related]
29. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
Zhu Y; Qin LX
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
[TBL] [Abstract][Full Text] [Related]
30. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
Chen X; Kou L; Xie X; Su S; Li J; Li Y
Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
[TBL] [Abstract][Full Text] [Related]
31. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.
Polidoro MA; Mikulak J; Cazzetta V; Lleo A; Mavilio D; Torzilli G; Donadon M
World J Gastroenterol; 2020 Sep; 26(33):4900-4918. PubMed ID: 32952338
[TBL] [Abstract][Full Text] [Related]
32. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
33. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract][Full Text] [Related]
34. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment.
Han R; Li J; Hony J; Xiao Z; Wang J; Yao M; Liang S; Lu L
Front Immunol; 2023; 14():1052657. PubMed ID: 37006233
[TBL] [Abstract][Full Text] [Related]
35. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Guardascione M; Toffoli G
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints.
Xu Y; He L; Fu Q; Hu J
Front Oncol; 2021; 11():759015. PubMed ID: 34858835
[TBL] [Abstract][Full Text] [Related]
38. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
39. Potent induction of antitumor immunity by combining cryo-thermal ablation with immune checkpoint inhibitors in hepatocellular carcinoma.
Qian L; Xie L; Zhu Y; Huang C; Meng Z
Liver Int; 2024 Mar; 44(3):723-737. PubMed ID: 38111027
[TBL] [Abstract][Full Text] [Related]
40. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]